Congressmembers Dina Titus and Ilhan Omar, Co-Chairs of the bipartisan Congressional Cannabis Caucus, today introduced the Evidence-Based Drug Policy Act of 2025.
Under current law, the Office of National Drug Control Policy (ONDCP) is prohibited from spending on or sponsoring any research related to the medical or recreational use of a Schedule 1 substance. Additionally, the Director of the ONDCP must oppose any attempt to legalize a substance that is listed under Schedule 1 and has not been approved for a medical purpose by the Food and Drug Administration.
The Evidence-Based Drug Policy Act removes these restrictions, allowing the executive branch’s drug policy advisor to take actions reflecting the current use of cannabis in the United States. This outdated prohibition is not based on science or reality. Removing this restriction would allow the ONDCP to conduct essential public policy analyses on states’ adult-use and medicinal cannabis programs and sponsor medical research on the benefits of cannabis. A 2024 National Academies study entitled, “Cannabis Policy Impacts Public Health and Health Equity”, specifically recommended Congress remove these restrictions so that ONDCP can support research on the impacts of changes in cannabis policy.
“The Office of National Drug Control Policy and its Director should be free to sponsor research or speak about substances like cannabis based on evidence and research,” said Congresswoman Titus. “Statutory restrictions on what can be studied and a mandate to oppose any attempts to reschedule substances like cannabis make no sense. It’s time to update the law to reflect the current use of cannabis in the United States and its medical benefits. The federal government needs to catch up to the states.”
“Our nation’s drug policies have been shaped by stigma. The American people overwhelmingly support cannabis reform, and yet the federal government continues to tie the hands of its own experts,” said Congresswoman Ilhan Omar. “The Evidence-Based Drug Policy Act is about bringing our laws into the 21st century, ensuring that the Office of National Drug Control Policy can do its job guided by facts, not outdated ideology. We need drug policy to follow the science and reflect the reality on the ground in states across the country.”
The Evidence-Based Drug Policy Act of 2025 is supported by the Drug Policy Alliance, the Nevada Cannabis Association, the National Cannabis Industry Association, the UNLV Cannabis Policy Institute, NORML, the Marijuana Policy Project, the Law Enforcement Action Partnership, the Parabola Center for Law and Policy, Doctors for Drug Policy Reform, the US Cannabis Roundtable, Cannabis Regulators of Color, Students for Sensible Drug Policy, the Minority Cannabis Business Association, and the Indigenous Cannabis Industry Association.
“The Drug Policy Alliance is proud to support the Evidence-Based Drug Policy Reform Act because it removes unnecessary barriers to ensure that the Office of National Drug Control Policy is empowered to develop drug policy based on evidence, not outdated political mandates,” said Cat Packer, Director of Drug Markets & Legal Regulation, Drug Policy Alliance. “To advance policies that support public health, promote fairness, and meet the needs of the American people, ONDCP must be free to study the full range of public policy approaches—including the impacts of cannabis policy changes such as legalization and regulation.”
“The Evidence-Based Drug Policy Act of 2025 is a smart, surgical fix to promote much needed cannabis research. By targeting one deeply flawed provision that blocks scientific research and prevents us from understanding the public health impacts of cannabis legalization, this bill allows the government to study what’s already happening in dozens of states,” said Riana Durrett, Director, UNLV Cannabis Policy Institute. “Representative Titus is championing rational, responsible, and long overdue access to research. This is a commendable effort to prevent our nation from continuing to fall behind other countries that are forging ahead and surpassing the United States in cannabis research.”
“We are proud to endorse this bill that would encourage the federal government to study the impacts of cannabis legalization. Despite the fact that over two-thirds of Americans live in jurisdictions that allow the medical use of cannabis and 24 states have legalized adult-use cannabis, the federal government has maintained restrictions on research aimed at understanding the impacts of these policy changes since their inception,” said Lauren Daly, Marijuana Policy Project Interim Executive Director. “With state-legal cannabis becoming increasingly accessible across the nation, it is imperative for the federal government to enable and support comprehensive research into cannabis legalization, ensuring that future policies are informed by sound evidence.”
“Mandating that a federal agency charged with supporting public health and safety must ignore scientific research and oppose evidence-based policies that have been embraced by dozens of states is simply bad law, and out of step with where the vast majority of Americans stand on cannabis issues,” said Morgan Fox, Political Director for the National Organization for the Reform of Marijuana Laws (NORML). “The ONDCP should have the liberty to look at all the available information and explore policy solutions free from outdated political restrictions. We commend the sponsors for introducing this long overdue legislation and urge Congress to approve it without delay.”
“On behalf of the Law Enforcement Action Partnership (LEAP), I write in strong support of the Evidence-Based Drug Policy Act,” said Lt. Diana Goldstein (Ret.), Law Enforcement Action Partnership Executive Director. “This legislation would give the Director of the Office of National Drug Control Policy (ONDCP) the freedom to consider funding research on Schedule I drugs and the ability to endorse any proposals to change the status of Schedule I drugs. As law enforcement professionals, we believe this act is essential for public health and safety.”
“The Cannabis Regulators of Color Coalition supports the Evidence-Based Drug Policy Reform Act because it affirms what communities and cannabis regulators across the country already know: federal drug policy must be guided by evidence, not ideology,” said Dasheeda Dawson, Board Chair, Cannabis Regulators of Color. “For more than a decade, tribal, state, and local governments have taken meaningful steps to repair the harms of criminalization and promote public health and safety through cannabis legalization and regulation. Empowering the Office of National Drug Control Policy to study these reforms is critical to developing federal policies that truly reflect the needs of everyday Americans—especially communities of color disproportionately impacted by prohibition.”
“We strongly support the Evidence-Based Drug Policy Act to ensure researchers have the ability to conduct rigorous research on medical cannabis and cannabis legalization,” said Charlie Bacthell, Acting Chairman, US Cannabis Roundtable. “The Department of Health and Human Services determined in 2023 that cannabis has low abuse potential and accepted medical use, and 80% of states allow some form of legal cannabis. Our nation’s research guidelines should reflect this reality.”
“The Minority Cannabis Business Association Board of Directors supports the Evidence-Based Drug Policy Act of 2025 introduced by Congresswoman Titus and Representative Omar. For too long, antiquated prohibitions have prevented critical research into cannabis, hampering our understanding of potential benefits and impacts,” said Frederika Easley, President, Minority Cannabis Business Association. “By removing these statutory barriers to research funding, this bill represents a crucial step toward creating evidence-based policies that can help address the ongoing harms of the War on Drugs, which have disproportionately affected communities of color. Science, not stigma, should guide our nation’s drug policies, and we applaud this legislation for embracing this principle. We urge Congress to pass this common-sense measure to allow research that will inform more equitable and effective approaches to cannabis regulation.”
“SSDP is proud to stand in support of the Evidence-Based Drug Policy Act of 2025 and commends Rep. Titus for her much-needed leadership on this issue. The science is clear and Americans on both sides of the aisle agree: marijuana does not belong on Schedule I of the Controlled Substances Act,” said Kat Muri, Executive Director, Students for Sensible Drug Policy. “By eliminating the ONDCP’s current legal requirement to oppose any efforts towards legalizing a Schedule I substance, this bill removes one of the biggest obstacles to legalizing cannabis at the federal level, and it does it in a very straightforward and clear way. It’s high time the U.S. replaces the disastrous and detrimental War on Drugs with policies rooted in evidence, compassion, and human rights—policies that make sense—and the Evidence-Based Drug Policy Act is an important step in that direction.”
“The Evidence-based Drug Policy Act of 2025 would pave the way for much-needed studies into cannabis, and we firmly believe those studies will show what Indigenous communities have always known—that plant-based medicine is a natural, beneficial way to treat ailments that is far superior to opioids and pharmaceuticals,” said Rob Pero (Bad River), founder of the Indigenous Cannabis Industry Association. “The criminalization of cannabis is doing more harm to our communities than good, and it’s time to take an evidence-based approach to correcting cannabis policy at the federal level.”
